Precigen, Inc. (FRA:I5X)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.18B +241.9% |
| Revenue (ttm) | 27.40M +652.1% |
| Net Income | -332.54M |
| EPS | -1.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 3.280 |
| Previous Close | 3.300 |
| Day's Range | 3.240 - 3.280 |
| 52-Week Range | 1.100 - 4.552 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2026 |
About Precigen
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops pro... [Read more]
Financial Performance
In 2025, Precigen's revenue was $9.68 million, an increase of 146.73% compared to the previous year's $3.93 million. Losses were -$429.64 million, 240.4% more than in 2024.
Financial numbers in USD Financial StatementsNews
Precigen presents long-term follow-up data from study of Papzimeos
Precigen (PGEN) announced updated long-term follow-up data from the study of Papzimeos for the treatment of adults with recurrent respiratory papillomatosis, RRP. Updated durability of response data w...
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP 5 complete responders have ongoing responses beyond 4 ...
Precigen price target raised to $14 from $11 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Precigen (PGEN) to $14 from $11 and keeps a Buy rating on the shares. The company announced that the FDA granted Papzimeos…
Precigen receives orphan drug exclusivity for papzimeos in the U.S.
Precigen (PGEN) announced that the FDA has granted orphan drug exclusivity for papzimeos – zopapogene imadenovec-drba – for the treatment of adults with recurrent respiratory papillomatosis, or RRP. P...
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
FDA grants orphan drug exclusivity for PAPZIMEOS for the treatment of adults with recurrent respiratory papillomatosis Seven-year period of PAPZIMEOS market exclusivity is effective through August 14,...
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
GERMANTOWN, Md., May 26, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve t...
Precigen price target raised to $11 from $10 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Precigen (PGEN) to $11 from $10 and keeps a Buy rating on the shares post the Q1 report. The firm says Papzimeos…
Precigen price target raised to $11 from $9 at Citizens
Citizens raised the firm’s price target on Precigen (PGEN) to $11 from $9 and keeps an Outperform rating on the shares. The firm is impressed by the strength of the…
Precigen reports Q1 EPS (2c) vs. (18c) last year
Reports Q1 revenue $23.25M, consensus $20.8M. “We are thrilled with the strength of the PAPZIMEOS launch and the pace of revenue growth as we drive broad commercial success across the…
Precigen Earnings Call Transcript: Q1 2026
PAPZIMEOS achieved $21.6M in Q1 2026 revenue, marking rapid adoption as the new RRP standard of care, with broad payer coverage and strong physician enthusiasm. Cash position is solid, with operations funded through 2026 and continued expansion expected.
Precigen Earnings release: Q1 2026
Precigen released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Precigen Quarterly report: Q1 2026
Precigen has published its Q1 2026 quarterly earnings report on May 13, 2026.
Precigen Reports First Quarter 2026 Financial Results and Business Updates
PAPZIMEOS™ launch gaining strong momentum with $21.6 million in net product revenue in the first quarter of 2026 reflecting broad-based uptake across the US Patient hub enrollment continues to gain tr...
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13
GERMANTOWN, Md., May 7, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve th...
Precigen Proxy statement: Proxy filing
Precigen filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Precigen Proxy statement: Proxy filing
Precigen filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Precigen sees Q1 revenue exceeding $18M, consensus $20.8M
“In the short time since early and full approval, the standard-of-care first-line treatment is seeing tremendous progress,” said Precigen’s (PGEN) President and CEO, Helen Sabzevari, during a conferen...
Precigen sees ‘robust uptake’ in usage of Papzimeos since its launch
Precigen (PGEN) announces it has seen “robust uptake” in usage of Papzimeos since launching the immunotherapy in August 2025. Additionally, the company announced that the Centers for Medicare and Medi...
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million
Plans Underway to Expand Use to Pediatrics, Patient Redosing and European Approval Meg Flippin, Benzinga Staff Writer GERMANTOWN, MD / ACCESS Newswire / April 7, 2026 / Precigen Inc. (NASDAQ:PGEN), a ...
Precigen Transcript: Fireside chat
PAPZIMEOS, the first immunotherapy for adult RRP, is driving a commercial transformation, with strong launch metrics, broad physician support, and robust payer access. The company is expanding its pipeline with pediatric trials, redosing studies, and new cancer indications leveraging its differentiated platform.
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
GERMANTOWN, Md., March 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve...
Precigen jumps on Q1 outlook despite earnings miss
Precigen (PGEN) shares are trading up almost 26% at $3.91 after the company reported quarterly results. The biotech company reported $9.7M in revenue, missing consensus estimates by $3.8M, but highlig...
Precigen price target raised to $10 from $9 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Precigen (PGEN) to $10 from $9 and keeps a Buy rating on the shares. The firm says Papzimeos sales are expected to…
Precigen price target raised to $9 from $8 at Citizens
Citizens raised the firm’s price target on Precigen (PGEN) to $9 from $8 and keeps an Outperform rating on the shares. Precigen reported Q4 updates highlighting strong early commercial traction…
Precigen Earnings Call Transcript: Q4 2025
PAPZIMEOS launch drove a 149% revenue increase in 2025, with Q1 2026 revenue expected to exceed $18 million. Broad payer coverage, strong physician uptake, and a permanent J-code are accelerating adoption, while European expansion and pediatric trials are underway.